uniQure N.V. (NASDAQ:QURE - Get Free Report) Director David D. Meek sold 2,112 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the transaction, the director now owns 34,190 shares in the company, valued at $494,045.50. This represents a 5.82% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
uniQure Price Performance
Shares of NASDAQ:QURE traded up $0.27 during midday trading on Tuesday, hitting $14.22. The company had a trading volume of 852,314 shares, compared to its average volume of 1,953,833. uniQure N.V. has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a debt-to-equity ratio of 1.53, a current ratio of 11.99 and a quick ratio of 11.99. The stock has a market cap of $778.97 million, a price-to-earnings ratio of -3.24 and a beta of 0.08. The business's 50-day simple moving average is $14.29 and its 200-day simple moving average is $13.99.
uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. The firm had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. On average, research analysts predict that uniQure N.V. will post -3.75 earnings per share for the current year.
Institutional Investors Weigh In On uniQure
Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Twin Tree Management LP acquired a new stake in uniQure during the fourth quarter worth $77,000. Mraz Amerine & Associates Inc. acquired a new stake in shares of uniQure in the first quarter valued at $106,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of uniQure in the first quarter valued at $152,000. ADAR1 Capital Management LLC acquired a new stake in shares of uniQure in the fourth quarter valued at $177,000. Finally, Wells Fargo & Company MN grew its stake in shares of uniQure by 13.9% in the fourth quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after buying an additional 1,503 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. Cantor Fitzgerald upgraded uniQure to a "strong-buy" rating in a research report on Monday, May 19th. Chardan Capital reiterated a "buy" rating and set a $38.00 price target on shares of uniQure in a research report on Friday, May 30th. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Guggenheim restated a "buy" rating and issued a $28.00 target price on shares of uniQure in a research report on Monday, May 12th. Finally, HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of uniQure in a research report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $37.82.
View Our Latest Research Report on QURE
About uniQure
(
Get Free Report)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider uniQure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and uniQure wasn't on the list.
While uniQure currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
